CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1688-1699

  Wang, Qi ^a   Tang, Yong ^a   Yu, Hongjing ^a   Yin, Qiaoyun ^a   Li, Mengdi ^a   Shi, Lijun ^a   Zhang, Wei ^a   Li, Danrong ^a   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

chemokine (C C motif) ligand 18; epithelial ovarian carcinoma; metastasis; signaling pathway

Indexed keywords

CCL 18 CHEMOKINE; CHEMOKINE; MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG; BETA CHEMOKINE; CCL18 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; CARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CC; FEMALE; HUMANS; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84949592698     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22419     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63:11–30.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519–2529.
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177:1053–1064.
4. Barbolina MV, Kim M, Liu Y, et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res 2010; 8:653–664.
5. Kim M, Rooper L, Xie J, Kajdacsy-Balla AA, Barbolina MV. Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res. 2012; 10:11–24.
6. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160:1411–1418.
7. Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers 2011; 26:262–273.
8. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009; 27:451–483.
9. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005; 78:14–26.
10. Chang CY, Lee YH, Leu SJ, et al. CC chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders. Neuroscience 2010; 165:1233–1243.
11. Leung SY, Yuen ST, Chu KM, et al. Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology 2004; 127:457–469.
12. Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms fromascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine inovarian carcinoma. J Biol Chem 2002; 277:24584–24593.
13. Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 2010; 27:1246–1253.
14. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91–102.
15. Chen J, Yao Y, Gong C, et al. CCL18 From tumor associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011; 19:541–555.
16. Catusse J, Wollner S, Leick M, Schröttner P, Schraufstätter I, Burger M. Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol 2010; 225:792–800.
17. Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med 2013; 210:1889–1898.
18. Li HY, Cui XY, Wu W, et al. Pyk2 and Src mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem. 2014; 115:596–603.
19. Zhang W, Yang YZ, Li L, Wang Q. Study of growth, invasion and metastasis on ovarian epithelial cancer cell line with CCL18 over-expression by mediated in vitro. Zhonghua Fu Chan Ke Za Zhi 2013; 48:528–531.
20. Angen L. Laser capture microdissection in the tissue biorepository. J Biomol Tech 2010; 21:120–125.
21. Butler GS, Dean RA, Morrison CJ, Overall CM. Methods in molecular biology. In: Clarke IM, editor. New York: Springer-Verlag Inc; 2010. pp. 451–470.
22. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56:279–285.
23. Larson Y, Liu J, Stevens PD, et al. Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem 2010; 285:24987–24998.
24. Livak K. ABI Prism 7700 Sequence Detection System User Bulletin #2 Relative quantification of gene expression. ABI company publication. 1997& 2001.
25. Gan CS, Chong PK, Pham TK, Wright PC. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007; 6:821–827.
26. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9–22.
27. Quesada AE, Nguyen ND, Rios A, Brown RE. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: Pathogenetic implications and therapeutic options. Int J Clin Exp Pathol 2014; 7:8732–8739.
28. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009; 30:1073–1081.
29. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013; 33:S79–S84.
30. Matsuo Y, Takeyama H, Guha S. Cytokine network: New targeted therapy for pancreatic cancer. Curr Pharm Des 2012; 18:2416–2419.
31. Cabioglu N, Sahin AA, Morandi P, et al. Chemokine receptors in advanced breast cancer: Differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 2009; 20:1013–1019.
32. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2004; 78:14.
33. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56:1685–1693.
34. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:717–723.
35. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS ONE 2012; 7:e37797.
36. Li D, Duell EJ, Yu K, et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 2012; 33:1384–1390.
37. Miyagaki T, Sugaya M, Suga H, et al. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: Association with disease severity and prognosis. J Eur Acad Dermatol Venereol 2013; 27:e60–e67.
38. Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011; 131:1322–1330.
39. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3:1154–1169.
40. Unwin RD, Griffiths JR, Whetton AD. Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc 2010; 5:1574–1582.
41. Velghe AI, Van Cauwenberghe S, Polyansky AA, et al. PDGFRA alterations in cancer: Characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2014; 33:2568–2576.
42. Kikuchi A, Monga SP. PDGFRα in liver pathophysiology: Emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr 2015; 16:109–127.
43. Kranenburg O. The KRAS oncogene: Past, present, and future. Biochim Biophys Acta 2005; 1756:81–82.
44. Efeyan A, Sabatini DM. MTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 2009; 22:169–176.
45. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19–24.
46. Yecies JL, Manning BD. MTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 2011; 89:221–228.
47. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159–168.
48. Guertin DA, Stevens DM, Saitoh M, et al. MTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15:148–159.
49. Maru S, Ishigaki Y, Shinohara N, Takata T, Tomosugi N, Nonomura K. Inhibition of mTORC2 but not mTORC1 up-regulates E-Cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. J Urol 2013; 189:1921–1929.
50. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010; 29:11–25.